CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 01/08/24

2024-01-08 09:33:32 ET More on Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript Cyclacel Pharmaceuticals announces registered direct and private placement offering For further details see: CYCC regains compliance wit...

BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it received a notification letter fro...

2024-01-08 08:46:55 ET Aclarion ( ACON ) +111% Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan. Harpoon Therapeutics  ( HARP ) +110% stock surges as Merck reportedly in talks for $700M acquisition. Ambrx Biopharma  ( ...

2024-01-05 10:00:03 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and uti...

BERKELEY HEIGHTS, N.J., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Spiro Rombotis, President & Chief...

BERKELEY HEIGHTS, N.J., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it has entered into a definitive agre...

- Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels - - A Squamous Non-Small Cell Lung Cancer Patient with CDKN2B Deletion Achieved Marked Tumor Shrinkage after One Cycle - - Retrospective Analysis Identified CDKN2A, CDKN2B an...

2023-12-12 16:17:20 ET More on Cyclacel Pharmaceuticals Seeking Alpha’s Quant Rating on Cyclacel Pharmaceuticals Historical earnings data for Cyclacel Pharmaceuticals Financial information for Cyclacel Pharmaceuticals For further details see: Cycla...

BERKELEY HEIGHTS, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will implement a 1-for-15 Reverse ...

2023-11-30 09:39:45 ET More on Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript Cyclacel Pharmaceuticals files for $100M mixed shelf offering - filing For further details see: Cyclacel Pharmaceuticals regains complia...